Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Diltiazem Inhibition of Cytochrome P-450 3A Activity Is Due To Metabolite Intermediate Complex Formation

David R. Jones, J. Christopher Gorski, Mitchell A. Hamman, Bradley S. Mayhew, Steven Rider and Stephen D. Hall
Journal of Pharmacology and Experimental Therapeutics September 1999, 290 (3) 1116-1125;
David R. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Christopher Gorski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitchell A. Hamman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley S. Mayhew
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Rider
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen D. Hall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Diltiazem (DTZ) N-demethylation occurs by cytochrome P-450 (CYP) 3A based on the following observations: 1) a single enzyme Michaelis-Menten model of metabolite formation, 2) high correlations of DTZ N-demethylation activity to other CYP3A activities, 3) inhibition of DTZ N-demethylation activity by triacetyloleandomycin, and 4) DTZ N-demethylation activity by expressed CYP3A enzymes only. The meanKms for DTZ N-demethylation in human liver microsomes and expressed CYP3A4(+b5) were 53 and 16 μM, respectively. A 30-min preincubation of DTZ in expressed CYPs inhibited CYP3A4(+b5) by 100%, of which 55% was due to formation of a metabolite intermediate complex (MIC), which is an inactive form of CYP. MIC was observed in human liver microsomes and cDNA-expressed CYP3A only. In experiments to assess simultaneous MIC formation and loss of CYP3A activity, DTZ caused greater than 80% inhibition of midazolam hydroxylation after a 60-min preincubation in human liver microsomes. The rate constants for MIC formation and loss of midazolam hydroxylation activity were equivalent for the line of best fit for both data sets, which illustrates that MIC formation causes the inhibition of CYP3A activity. The mechanistic inhibition was characterized in expressed CYP3A4(+b5), which exhibited a concentration-dependent formation of MIC by DTZ (1–100 μM) with an estimated kinact of 0.17 min−1 and KI of 2.2 μM. The partition ratio for expressed CYP3A4(+b5) was substrate concentration dependent and varied from 13 to 86. This study showed that DTZ inhibition of CYP3A substrate metabolism occurs primarily by MIC formation.

Footnotes

  • Send reprint requests to: David R. Jones, Ph.D., Indiana University School of Medicine, Division of Clinical Pharmacology, Wishard Memorial Hospital, OPW 320, 1001 W. 10th St., Indianapolis, IN 46202. E-mail: drjones1{at}iupui.edu

  • ↵1 This work was supported in part by a grant (AG 13718) from the National Institutes of Health (Bethesda, MD).

  • Abbreviations:
    DTZ
    diltiazem
    α-NF
    α-naphthoflavone
    AUC
    area under the plasma concentration time curve
    Clint
    intrinsic clearance
    CYP
    cytochrome P-450
    kcat
    rate constant for catalysis
    kinact
    rate constant for inactivation
    Ki
    dissociation constant for reversible inhibition
    KI
    inactivator concentration that produces half the maximal rate of inactivation
    λ
    pseudo first-order rate constant
    MA
    N-desmethyl diltiazem
    MIC
    metabolite intermediate complex
    MICmax
    maximum metabolite intermediate complex
    r
    partition ratio
    Vmax
    maximum velocity of metabolite formation
    • Received December 7, 1998.
    • Accepted May 21, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 290 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 290, Issue 3
1 Sep 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Diltiazem Inhibition of Cytochrome P-450 3A Activity Is Due To Metabolite Intermediate Complex Formation
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Diltiazem Inhibition of Cytochrome P-450 3A Activity Is Due To Metabolite Intermediate Complex Formation

David R. Jones, J. Christopher Gorski, Mitchell A. Hamman, Bradley S. Mayhew, Steven Rider and Stephen D. Hall
Journal of Pharmacology and Experimental Therapeutics September 1, 1999, 290 (3) 1116-1125;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Diltiazem Inhibition of Cytochrome P-450 3A Activity Is Due To Metabolite Intermediate Complex Formation

David R. Jones, J. Christopher Gorski, Mitchell A. Hamman, Bradley S. Mayhew, Steven Rider and Stephen D. Hall
Journal of Pharmacology and Experimental Therapeutics September 1, 1999, 290 (3) 1116-1125;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Meeting Report for the ASPET–Ray Fuller Symposium: Cellular Mechanisms and Novel Strategies for Pain Control
  • Antinociceptive Properties of Fenfluramine, a Serotonin Reuptake Inhibitor, in a Rat Model of Neuropathy
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics